NEURO61

Session information

Print

Hot Topics

[HT-09] Hot Topics 09
Is the concept of embolic stroke of undertermined source (ESUS) dead or alive?

Tue. Sep 1, 2020 10:45 AM - 12:15 PM Room 1 (OKAYAMA CONVENTION CENTER 4F 405)

Chair：KazunoriToyoda（Dept. of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center）,TakanariKitazono（Department of Medicine and Clinical Science）

[HT-09-1] Problems of ESUS criteria from the viewpoint of the guidelines for implantable cardiac monitor

○Keiji Yamaguchi (Department of Neurology, Ichinomiya Nishi Hospital, Japan)

Two clinical trials to compare direct oral anticoagulants (DOACs) and aspirin did not show superiority of DOACs over aspirin in patients with embolic stroke of undertermined source (ESUS). It is argued on the reasons for the negative results that covert atrial fibrilltion may not be a major cause and arteriogenic embolism may be prevalent than ever thought. In this symposium, we analyze the factors affecting the results, reconsider the the currrent concept of EUS, and perspect future direction of antithrombotic therapy.

[HT-09-2] Investigation of arteriogenic embolism

○Yuji Ueno1, Takao Urabe2, Nobutaka Hattori1 (1.Department of Neurology, Juntendo University Faculty of Medicine, Japan, 2.Department of Neurology, Juntendo University Urayasu Hospital, Japan)

Two clinical trials to compare direct oral anticoagulants (DOACs) and aspirin did not show superiority of DOACs over aspirin in patients with embolic stroke of undertermined source (ESUS). It is argued on the reasons for the negative results that covert atrial fibrilltion may not be a major cause and arteriogenic embolism may be prevalent than ever thought. In this symposium, we analyze the factors affecting the results, reconsider the the currrent concept of EUS, and perspect future direction of antithrombotic therapy.

[HT-09-3] Decision making of patent foramen ovale closure by brain and heart team

○Hiroshi Yamagami (Department of Stroke Neurology, National Hospital Organization Osaka National Hospital, Japan)

Two clinical trials to compare direct oral anticoagulants (DOACs) and aspirin did not show superiority of DOACs over aspirin in patients with embolic stroke of undertermined source (ESUS). It is argued on the reasons for the negative results that covert atrial fibrilltion may not be a major cause and arteriogenic embolism may be prevalent than ever thought. In this symposium, we analyze the factors affecting the results, reconsider the the currrent concept of EUS, and perspect future direction of antithrombotic therapy.

[HT-09-4] Subclassification of ESUS according to the responsiveness to anticoagulation

○Shinichiro Uchiyama (Center for Brain and Cerebral Vessels, Sanno Hospital and Sanno Medical Center, Japan)

Two clinical trials to compare direct oral anticoagulants (DOACs) and aspirin did not show superiority of DOACs over aspirin in patients with embolic stroke of undertermined source (ESUS). It is argued on the reasons for the negative results that covert atrial fibrilltion may not be a major cause and arteriogenic embolism may be prevalent than ever thought. In this symposium, we analyze the factors affecting the results, reconsider the the currrent concept of EUS, and perspect future direction of antithrombotic therapy.

[HT-09-5] Atrial cariopathy as a cause of ESUS

○Hans C. Diener (Faculty of Medicine and Institute for Med-ical Informatics, Biometry and Epidemiol-ogy at the University of Duisburg-Essen, Germany)

Two clinical trials to compare direct oral anticoagulants (DOACs) and aspirin did not show superiority of DOACs over aspirin in patients with embolic stroke of undertermined source (ESUS). It is argued on the reasons for the negative results that covert atrial fibrilltion may not be a major cause and arteriogenic embolism may be prevalent than ever thought. In this symposium, we analyze the factors affecting the results, reconsider the the currrent concept of EUS, and perspect future direction of antithrombotic therapy.